Parkinson’S Disease: Molecular Mechanisms And Treatments,
2012
Liberty University
Parkinson’S Disease: Molecular Mechanisms And Treatments, Delia Vahey
Senior Honors Theses
Parkinson’s disease is a motor system disorder that is caused primarily by the loss of dopamine-producing brain cells. The most affected brain structure is the pars compacta of the substantia nigra. This area of the brain is essential to the control of voluntary movement, and so its impairment leads to symptoms such as tremors, rigidity, and impaired balance. The neuronal protein alpha-synuclein has been shown to be heavily involved in the pathogenesis of the disease at the cellular level. The currently available treatments for PD mainly target dopamine regulation, and there been no cure developed for the disease at present. …
From A Paralyzed Genius, Lessons Of Determination And Caregiving For The Huntington's Community,
2012
University of San Diego
From A Paralyzed Genius, Lessons Of Determination And Caregiving For The Huntington's Community, Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
The Team Hope Walk: Reinforcing The First Line Of Defense Against Huntington's Disease,
2012
University of San Diego
The Team Hope Walk: Reinforcing The First Line Of Defense Against Huntington's Disease, Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
Biotinidase Deficiency In Pakistani Children; What Needs To Be Known And Done,
2012
Aga Khan University
Biotinidase Deficiency In Pakistani Children; What Needs To Be Known And Done, Bushra Afroze, Mohammad Wasay
Department of Medicine
No abstract provided.
A New, More Holistic View Of Huntington’S Disease: The Systems/P4 Approach,
2012
University of San Diego
A New, More Holistic View Of Huntington’S Disease: The Systems/P4 Approach, Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
The First Dose Is Hope: Moving Towards Treatments For Huntington's Disease,
2012
University of San Diego
The First Dose Is Hope: Moving Towards Treatments For Huntington's Disease, Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
Microrna-Regulated, Systemically Delivered Raav9: A Step Closer To Cns-Restricted Transgene Expression,
2012
University of Massachusetts Medical School
Microrna-Regulated, Systemically Delivered Raav9: A Step Closer To Cns-Restricted Transgene Expression, Jun Xie, Qing Xie, Hongwei Zhang, Stefan L. Ameres, Jui-Hung Hung, Qin Su, Ran He, Xin Mu, Seemin Seher Ahmed, Soyeon Park, Hiroki Kato, Chengjian Li, Christian Mueller, Craig C. Mello, Zhiping Weng, Terence R. Flotte, Phillip D. Zamore, Guangping Gao
Christian Mueller
Recombinant adeno-associated viruses (rAAVs) that can cross the blood-brain-barrier and achieve efficient and stable transvascular gene transfer to the central nervous system (CNS) hold significant promise for treating CNS disorders. However, following intravascular delivery, these vectors also target liver, heart, skeletal muscle, and other tissues, which may cause untoward effects. To circumvent this, we used tissue-specific, endogenous microRNAs (miRNAs) to repress rAAV expression outside the CNS, by engineering perfectly complementary miRNA-binding sites into the rAAV9 genome. This approach allowed simultaneous multi-tissue regulation and CNS-directed stable transgene expression without detectably perturbing the endogenous miRNA pathway. Regulation of rAAV expression by miRNA …
Top Researcher: ‘Genuine Optimism’ About Treatments For Huntington's Disease,
2012
University of San Diego
Top Researcher: ‘Genuine Optimism’ About Treatments For Huntington's Disease, Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
It’S Time For The Huntington’S Community To Speak Out - And Hdsa Is Listening,
2012
University of San Diego
It’S Time For The Huntington’S Community To Speak Out - And Hdsa Is Listening, Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
The Quandary Of Denial In The Huntington’S Disease Community (Part Ii),
2012
University of San Diego
The Quandary Of Denial In The Huntington’S Disease Community (Part Ii), Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
The Quandary Of Denial In The Huntington’S Disease Community (Part I),
2012
University of San Diego
The Quandary Of Denial In The Huntington’S Disease Community (Part I), Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
To Strive Or To Chill? Seeking Balance In The Fight Against Huntington's Disease,
2012
University of San Diego
To Strive Or To Chill? Seeking Balance In The Fight Against Huntington's Disease, Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
Advocacy Pays Off: Huntington’S Disease Stem-Cell Research Advances In California,
2012
University of San Diego
Advocacy Pays Off: Huntington’S Disease Stem-Cell Research Advances In California, Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
Let’S Turn Grief For ‘Hd Angels’ Into New Impetus For The Huntington's Cure,
2012
University of San Diego
Let’S Turn Grief For ‘Hd Angels’ Into New Impetus For The Huntington's Cure, Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
Ginkgo Extract Egb761 Confers Neuroprotection By Reduction Of Glutamate Release In Ischemic Brain,
2012
Texas Tech University Health Science Center
Ginkgo Extract Egb761 Confers Neuroprotection By Reduction Of Glutamate Release In Ischemic Brain, Alexander Mdzinarishvili, Rachita K. Sumbria, Dorothee Lang, Jochen Klein
Pharmacy Faculty Articles and Research
Purpose - Ginkgo extract EGb761 has shown anti-edema and anti-ischemic effects in various experimental models. In the present study, we demonstrate neuroprotective effects of EGb761 in experimental stroke while monitoring brain metabolism by microdialysis. Methods - We have used oxygen-glucose deprivation in brain slices in vitro and middle cerebral artery occlusion (MCAO) in vivo to induce ischemia in mouse brain. We used microdialysis in mouse striatum to monitor extracellular concentrations of glucose and glutamate. Results - In vitro, EGb761 reduced ischemia-induced cell swelling in hippocampal slices by 60%. In vivo, administration of EGb761 (300 mg/kg) reduced cell degeneration and edema …
Seven Years Of Striving For A Realistic And Unapologetic View Of Huntington's Disease,
2012
University of San Diego
Seven Years Of Striving For A Realistic And Unapologetic View Of Huntington's Disease, Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
Striving For Brave New Brains,
2012
University of San Diego
Striving For Brave New Brains, Kenneth P. Serbin
At Risk for Huntington's Disease
No abstract provided.
Notch Regulation Of Adam12 Expression In Glioblastoma Multiforme,
2012
University of Massachusetts Amherst
Notch Regulation Of Adam12 Expression In Glioblastoma Multiforme, Ala'a S. Alsyaideh
Masters Theses 1911 - February 2014
Glioblastoma is the most common malignant brain tumor, accounting for 17% of all primary brain tumors in the United States. Despite the available surgical, radiation, and chemical therapeutic options, the invasive and infiltrative nature of the tumor render current treatment options minimally effective. Recent reports have identified multiple regulators of glioblastoma progression and invasiveness. It has been demonstrated that ADAM12, A Disintegrin And Metalloproteinase encoded by ADAM12 gene, is over-expressed in glioblastoma and directly correlated with tumor proliferation. Additionally, dysregulation of the Notch signaling pathway has been implicated in the pathogenesis of many gliomas. Lastly, an evolving role of microRNAs, …
Normal Pressure Hydrocephalus: How Can It Be Told Apart From Neurodegenerative Diseases Of The Elderly?,
2012
Touro College
Normal Pressure Hydrocephalus: How Can It Be Told Apart From Neurodegenerative Diseases Of The Elderly?, Raphael C. Zohn
The Science Journal of the Lander College of Arts and Sciences
Normal pressure hydrocephalus (NPH) affects more of the older population than people recognize. The underestimation of this neurological condition is due in most part to the overlap of its symptoms to other forms of dementia as well as many other geriatric conditions. The objective of this paper was to research and contrast various methods of differentiation in the diagnosis of normal pressure hydrocephalus as well as find pretreatment indicators of successful surgery. Methods included reviewing of articles and studies done to evaluate which symptoms are most commonly presented in normal pressure hydrocephalus and their subtle differences from the symptoms of …
Treatment Options For Parkinson’S Disease,
2012
Touro College
Treatment Options For Parkinson’S Disease, Sara Russ
The Science Journal of the Lander College of Arts and Sciences
The following is an excerpt from this article: Parkinson’s disease was first described and named Paralysis Agitans in 1817 by British physician James Parkinson (Lieberman 2004). Later on, it took on its current name after Dr. Parkinson. Parkinson’s disease (PD) is a neurological disorder for which the cause is yet to be discovered. Like many other diseases, PD has numerous facets. Throughout all of its different stages, it presents with motor, as well as nonmotor, symptoms (Simuni et al. 2009). Though estimates of people affected by PD are constantly being made, it is difficult to determine a precise and accurate …
